Jing Yang

Dr. Jing Yang


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 February 2022 in JCI Insight
Verified
Journal Article
Open access
PDF file
JYJing Yang
Jing Yang
HLHongxia Li
Hongxia Li
CZChi Zhang
Chi Zhang
YZYafeng Zhou
Yafeng Zhou
There is a high prevalence of ventricular arrhythmias related to sudden cardiac death in patients with chronic kidney disease (CKD). To explored the possible mechanism of CKD-related ventricular arrhythmias, a CKD rat model was created, and indoxyl sulfate (IS) was further used in vivo and in vitro. This project used the following methods: patch clamp, electrocardiogram, and some molecular biology experimental techniques. IS was found to be significantly elevated in the serum of CKD rats. Interestingly, the expression levels of the fast transient outward potassium current–related (I to,f -related) proteins (Kv4.2, Kv4.3, and KChIP2) in the heart of CKD rats and rats treated with IS decreased. IS dose-dependently reduced I to,f density, accompanied by the decreases in Kv4.2, Kv4.3, and KChIP2 proteins in vitro. IS also prolonged the action potential duration and QT interval, and paroxysmal ventricular tachycardia could be induced by IS. In-depth studies have shown that ROS/p38MAPK, ROS–p44/42 MAPK, and NF-κB signaling pathways play key roles in the reduction of I to,f density and I to,f -related proteins caused by IS. These data suggest that IS reduces I to,f -related proteins and I to,f density by activating ROS/MAPK and NF-κB signaling pathways, and the action potential duration and QT interval are subsequently prolonged, which contributes to increasing the susceptibility to arrhythmia in CKD.

22 January 2025 in Clinical and Applied Thrombosis/Hemostasis
Verified
Journal Article
Open access
HCHan Cheng
Han Cheng
HYHaozhe Yang
Haozhe Yang
YZYantong Zhang
Yantong Zhang
ZWZhanxu Wei
Zhanxu Wei
LXLei Xia
Lei Xia
JYJing Yang
Jing Yang
Background: Venous thromboembolism (VTE) comprises deep vein thrombosis (DVT) and pulmonary embolism (PE). Chronic thromboembolic pulmonary hypertension (CTEPH) typically arises from acute pulmonary embolism. The pathogenesis of them involves multiple risk factors such as genetic predisposition. However, the findings from these studies are not entirely consistent. This study aims to investigate the association between FGA rs6050 polymorphism and susceptibility to thrombotic diseases. Methods: We searched PubMed, OVID, Web of Science, Academic Search Ultimate, CNKI, and Wan Fang database. To assess the strength of associations, we calculated pooled odds ratios (ORs) and 95% confidence intervals (CIs) in different genetic models. Additionally, subgroup analyses, sensitivity analysis, and assessment of publication bias were also carried out. Results: A total of 11 studies, including 9 reported results on VTE (3856 individuals [1545 cases]) and 3 on CTEPH (761 participants [350 cases]), revealed a significant association between the rs6050 polymorphism and susceptibility to both VTE and CTEPH. The A allele was consistently linked to an elevated risk of VTE across all genetic models (allele, homozygote, heterozygote, recessive, and dominant model), while it was also associated with an increased risk of CTEPH under all genetic models excluding the recessive model. Furthermore, subgroup analysis among ethnic groups revealed a significant association between rs6050 polymorphisms and VTE in both Caucasians and Asians under all genetic models. In Africans, the association with VTE was only observed for rs6050 polymorphisms in dominant and heterozygous models. Conclusions: The FGA rs6050 polymorphism is positively associated with susceptibility to VTE and CTEPH.

26 November 2025 in World Journal of Cardiology
Verified
Journal Article
Open access
ACAngat Naresh Chadha
Angat Naresh Chadha
HCHan Cheng
Han Cheng
JYJing Yang
Jing Yang
SRY-related high-mobility group box 9 (SOX9) is an indispensable transcription factor that regulates multiple developmental pathways related to stem cell differentiation and progenitor cell development. Several studies have investigated the role of SOX9 in chondrogenesis and oncogenesis. Significant research exists describing the role of SOX9 in embryological development of the cardiovascular system. However, there is limited research exploring the roles of SOX9 in development of cardiovascular diseases. In this review we highlight and review the biology and contributions of SOX9 in embryologic cardiac development and shed some light on its participation in the development of myocardial fibrosis, which in turn leads to a wide variety of adverse cardiac outcomes.

26 August 2025 in World Journal of Cardiology
Verified
Journal Article
Open access
HCHan Cheng
Han Cheng
LGLing-Tong Gu
Ling-Tong Gu
JYJing Yang
Jing Yang
BACKGROUND Pheochromocytoma, a rare catecholamine-secreting tumor, typically presents with the classic triad of headache, palpitations, and diaphoresis, often accompanied by cardiovascular manifestations. While vomiting occurs in approximately 34.5% of cases, it is rarely the predominant and persistent presenting symptom. Pheochromocytoma-induced cardiomyopathy leading to heart failure is a recognized but uncommon complication. Due to its heterogeneous presentations, misdiagnosis and diagnostic delay are frequent. CASE SUMMARY A 53-year-old female presented predominantly with persistent and refractory vomiting as her chief complaint, accompanied by signs of acute heart failure [left ventricular ejection fraction (LVEF) 30%]. Initial evaluation at a primary hospital, including coronary angiography (revealing only mild stenosis), led to a misdiagnosis of coronary artery disease. Despite standard anti-thrombotic, anti-heart failure, and anti-emetic therapy, her vomiting persisted and heart failure did not resolve. Subsequent hospitalization revealed dramatic paroxysmal hypertension (202/129 mmHg to 97/51 mmHg) and fever. Significantly elevated plasma metanephrines and normetanephrine, combined with abdominal computed tomography and magnetic resonance imaging, confirmed a right adrenal pheochromocytoma. This diagnosis was significantly delayed due to the atypical prominence of gastrointestinal symptoms masking the underlying endocrine crisis. CONCLUSION This case highlights a highly atypical presentation of pheochromocytoma dominated by refractory vomiting and complicated by acute catecholamine-induced cardiomyopathy. It emphatically underscores that pheochromocytoma must be considered in the differential diagnosis for patients presenting with unexplained, treatment-resistant vomiting, particularly when co-existing with acute heart failure. The presence of labile hypertension, even if not initially evident, provides a crucial diagnostic clue. Prompt biochemical screening (catecholamine metabolites) and adrenal imaging are essential to prevent diagnostic delay and enable timely, life-saving surgical intervention.

11 July 2026 in BMC Cardiovascular Disorders
Verified
Journal Article
Open access
PDF file
HDHaoze Deng
Haoze Deng
MXMengdie Xia
Mengdie Xia
YLYiyang Li
Yiyang Li
JYJing Yang
Jing Yang
XQXiaodong Qian
Xiaodong Qian
Aluminum oxide nanoparticles (Al₂O₃-NPs) are currently widely applied, although they are known to induce electrocardiographic abnormalities, th

18 December 2025 in World Journal of Transplantation
Verified
Journal Article
Open access
HCHan Cheng
Han Cheng
LXLei Xia
Lei Xia
HYHao-Zhe Yang
Hao-Zhe Yang
ZWZhan-Xu Wei
Zhan-Xu Wei
YZYan-Tong Zhang
Yan-Tong Zhang
JYJing Yang
Jing Yang
This article comments on the research by Zhang et al on the role of advanced heart failure and transplant teams in extracorporeal membrane oxygenation (ECMO) management. The study by Zhang et al indicates that direct advanced heart failure and transplant involvement improves survival in ECMO patients, especially those on veno-arterial ECMO. However, the optimal approach varies due to multiple factors. This article discusses the clinical implications, research design limitations, and future directions to enhance ECMO care.